- Home
- SGMT
as 02-21-2025 4:00pm EST
Stocks
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 165.4M | IPO Year: | 2023 |
| Target Price: | $25.71 | AVG Volume (30 days): | 864.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.39 - $7.64 | Next Earning Date: | 03-24-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Sagimet Biosciences Inc. Series A News
SGMT Breaking Stock News: Dive into SGMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
Simply Wall St.
17 days ago
US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks
GlobeNewswire
2 months ago
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Simply Wall St.
2 months ago
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
TipRanks
2 months ago
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
3 months ago
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
3 months ago
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Simply Wall St.
3 months ago
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
Compare SGMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMT Sagimet Biosciences Inc. Series A - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.